NZYM-B.CONZYM-B.COCPH
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -56.51% | -84.23% | -85.09% | +6.51% | +948.32% |
| Gross Profit Growth | -58.05% | -79.23% | -80.97% | -11.19% | +899.11% |
| EBITDA Growth | -58.25% | -75.51% | -80.48% | -3.83% | +369.03% |
| Operating Income Growth | -71.55% | -47.27% | -61.77% | +7.11% | +210.06% |
| Net Income Growth | -65.34% | -21.96% | -42.60% | +14.22% | +279.13% |
| EPS Growth | -78.97% | -53.49% | -66.28% | -31.79% | +316.98% |
| EPS Diluted Growth | -78.88% | -53.49% | -66.28% | -31.79% | +266.04% |
| Weighted Average Shares Growth | +64.16% | +67.33% | +69.75% | +67.57% | -9.17% |
| Weighted Average Shares Diluted Growth | +63.94% | +67.33% | +69.75% | +67.57% | +3.48% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -56.17% | -94.60% | -83.75% | -74.55% | +0.00% |
| Free Cash Flow Growth | -46.00% | -96.51% | -83.76% | -65.50% | +0.00% |
| Receivables Growth | -78.67% | -83.21% | +7.38% | -82.40% | +0.00% |
| Inventory Growth | -80.13% | -85.76% | -84.41% | -86.19% | +0.00% |
| Asset Growth | -46.48% | -86.77% | -85.58% | -85.61% | +0.00% |
| Book Value per Share Growth | -51.30% | -91.82% | -92.29% | -92.31% | +0.00% |
| Debt Growth | -76.76% | -88.55% | -77.61% | -76.81% | +0.00% |
| R&D Expense Growth | -58.26% | -85.21% | -84.89% | +8.58% | +247.30% |
| SG&A Expenses Growth | -51.78% | -84.17% | -83.58% | +13.23% | +307.27% |